Professor Zhiming Li: Addressing the Challenges of NK/T-Cell Lymphoma with a China-Specific Approach | 2026 CACA Western Integrated Oncology Conference

Professor Zhiming Li: Addressing the Challenges of NK/T-Cell Lymphoma with a China-Specific Approach | 2026 CACA Western Integrated Oncology Conference

To further promote the expansion, equitable distribution, and accessibility of high-quality cancer care resources, and to enhance the academic and clinical capabilities of oncology care in western China and at the grassroots level, the 2026 CACA Western Integrated Oncology Conference was successfully held in Chengdu on April 18, 2026. The conference provided a high-level platform for academic exchange and translational collaboration in oncology.
Professor Tongyu Lin: Harnessing Integration to Reshape Oncology Care and Redefine Humanistic Medicine | 2026 CACA Western Integrated Oncology Conference

Professor Tongyu Lin: Harnessing Integration to Reshape Oncology Care and Redefine Humanistic Medicine | 2026 CACA Western Integrated Oncology Conference

Amid the vibrant renewal of spring, the 2026 CACA Western Integrated Oncology Conference was grandly convened in Chengdu, Sichuan. The meeting brought together leading oncology experts from across China to explore the frontiers of precision oncology and advance the practice of integrated, whole-course cancer care.
Professor Xiaofan Zhu: Advancing Collaboration, Standardization, and Innovation to Shape a New Blueprint for Pediatric Leukemia Care | 2026 CACA Western Integrated Oncology Conference

Professor Xiaofan Zhu: Advancing Collaboration, Standardization, and Innovation to Shape a New Blueprint for Pediatric Leukemia Care | 2026 CACA Western Integrated Oncology Conference

To further expand access to high-quality cancer care resources, promote equitable distribution, and enhance the academic and clinical capacity of oncology care in western China and at the grassroots level, the 2026 CACA Western Integrated Oncology Conference was successfully held in Chengdu on April 18, 2026. The conference provided a high-level platform for academic exchange and translational collaboration in oncology.
Leading the Frontier, Shaping the Future | The Inaugural CSH–IACH Joint Symposium on “From Classics to Innovation: Advances in CAR-T Therapy” Successfully Concluded

Leading the Frontier, Shaping the Future | The Inaugural CSH–IACH Joint Symposium on “From Classics to Innovation: Advances in CAR-T Therapy” Successfully Concluded

The diagnosis and treatment of hematologic diseases remain a global challenge. In recent years, with the rapid emergence of innovative therapies such as chimeric antigen receptor T-cell (CAR-T) therapy and the deepening understanding of hematologic disorders, the field has entered a new era.
AACR 2026 | Qilu Pharmaceutical Showcases 12 Innovative Programs on the Global Stage: A Comprehensive Overview of ADCs, TCEs, Small-Molecule Inhibitors, and a Precision Oncology Portfolio

AACR 2026 | Qilu Pharmaceutical Showcases 12 Innovative Programs on the Global Stage: A Comprehensive Overview of ADCs, TCEs, Small-Molecule Inhibitors, and a Precision Oncology Portfolio

At the recently concluded 2026 Annual Meeting of the American Association for Cancer Research (AACR), Qilu Pharmaceutical presented 12 innovative oncology programs, including one oral presentation and eleven poster presentations. These studies span a wide range of tumor types, including gynecologic cancers, breast cancer, esophageal cancer, lung cancer, head and neck cancers, colorectal cancer, prostate cancer, diffuse large B-cell lymphoma (DLBCL), and acute myeloid leukemia (AML).
CSCO Guidelines Conference 2026 | Professor Jun Zhu: Redefining the Future of Lymphoma Care—Guideline Updates Shaping a “China Solution”

CSCO Guidelines Conference 2026 | Professor Jun Zhu: Redefining the Future of Lymphoma Care—Guideline Updates Shaping a “China Solution”

To advance clinical oncology in China, enhance physicians’ diagnostic and research capabilities, and further promote the development and implementation of CSCO guidelines, the Chinese Society of Clinical Oncology (CSCO), together with the Beijing CSCO Clinical Oncology Research Foundation, co-hosted the 2026 CSCO Guidelines Conference in Harbin from April 24 to 25.
CSCO Guidelines Conference 2026 | Professor Jun Ma: Illuminating Standardized Care Through Guidelines—Driving High-Quality Development of Oncology Practice in China

CSCO Guidelines Conference 2026 | Professor Jun Ma: Illuminating Standardized Care Through Guidelines—Driving High-Quality Development of Oncology Practice in China

To advance clinical oncology in China, enhance physicians’ diagnostic and research capabilities, and further promote the development and implementation of CSCO guidelines, the Chinese Society of Clinical Oncology (CSCO), together with the Beijing CSCO Clinical Oncology Research Foundation, co-hosted the 2026 CSCO Guidelines Conference in Harbin from April 24 to 25.
EBMT Global Perspective | Professor Donal McLornan: Defining Remission Criteria and Optimizing Novel Combination Strategies for Bone Marrow Transplantation in MDS/MPN Overlap Syndromes

EBMT Global Perspective | Professor Donal McLornan: Defining Remission Criteria and Optimizing Novel Combination Strategies for Bone Marrow Transplantation in MDS/MPN Overlap Syndromes

Myelodysplastic/myeloproliferative neoplasm (MDS/MPN) overlap syndromes are rare hematologic malignancies characterized by marked clinical heterogeneity and significant diagnostic and therapeutic challenges. Allogeneic hematopoietic stem cell transplantation remains a key treatment option; however, the lack of standardized criteria for assessing post-transplant remission and relapse represents a major unmet clinical need.